Corporate Profile

We are a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Our selective dismutase mimetic product candidate avasopasem manganese (avasopasem or GC4419) is being evaluated for radiotherapy-induced toxicities. Our second product candidate, rucosopasem manganese (rucosopasem or GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.